The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation
Journal of Korean Medical Science
;
: 79-82, 2004.
Article
Dans Anglais
| WPRIM
| ID: wpr-20648
ABSTRACT
Major ABO incompatibility may be potentially associated with immediate or delayed hemolysis and delayed onset of erythropoiesis in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). To determine if hemolysis can be prevented by the inhibition of graft erythropoiesis, we performed hypertransfusion and assessed red cell transfusion requirement and independence. Between October 1995 and December 2001, 28 consecutive patients receiving major ABO incompatible HSCT at Samsung Medical Center were hypertransfused to maintain their hemoglobin levels at 15 g/dL or more. We retrospectively compared the outcomes of these patients with those of 47 patients at Asan Medical Center whose target hemoglobin levels were 10 g/dL. Reticulocyte engraftment was significantly delayed in hypertransfused group (51 days vs. 23 days; p= .001). There was no significant difference in the total amount of red cells transfused within 90 days post-HSCT (25 units vs. 26 units; p= .631). No significant difference in the time to red cell transfusion independence was observed between the two groups (63 days vs. 56 days; p=.165). In conclusion, we failed to improve red cell transfusion requirement and independence in major ABO incompatible HSCT with hypertransfusion.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Facteurs temps
/
Transplantation homologue
/
Transfusion sanguine
/
Système ABO de groupes sanguins
/
Hémoglobines
/
Études rétrospectives
/
Résultat thérapeutique
/
Transplantation de cellules souches
/
Érythrocytes
/
Érythropoïèse
Type d'étude:
Étude observationnelle
Limites du sujet:
Adolescent
/
Adulte
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Journal of Korean Medical Science
Année:
2004
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS